MARKET

JNJ

JNJ

Johnson & Johnson
NYSE
237.00
+4.84
+2.08%
After Hours: 237.00 0 0.00% 19:26 06/09 EDT
OPEN
232.38
PREV CLOSE
232.16
HIGH
237.71
LOW
230.41
VOLUME
8.35M
TURNOVER
--
52 WEEK HIGH
250.27
52 WEEK LOW
145.41
MARKET CAP
570.51B
P/E (TTM)
27.41
1D
5D
1M
3M
1Y
5Y
1D
Biotech stocks are losing momentum despite rising M&A activity
Seeking Alpha · 9h ago
Notable ETF Inflow Detected - VONV, JNJ, WMT, CAT
NASDAQ · 12h ago
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
NASDAQ · 13h ago
Scotiabank Sticks to Their Buy Rating for Johnson & Johnson (JNJ)
TipRanks · 14h ago
Johnson & Johnson's Nipocalimab Gets U.K.'s Medicines And Healthcare Products Regulatory Agency Authorization To Treat Adults And Adolescents With Generalised Myasthenia Gravis
Benzinga · 15h ago
Kenvue: After A Disappointing 3 Years, Kimberly-Clark's Gamble Could Revive Growth
Seeking Alpha · 15h ago
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results
Barchart · 19h ago
Prediction: The Trump Bull Market Will Soon End -- But These 2 Stocks Will Keep Winning Anyway
The Motley Fool · 1d ago
More
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

Webull offers Johnson & Johnson stock information, including NYSE: JNJ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JNJ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JNJ stock methods without spending real money on the virtual paper trading platform.